| Cell line name |
HCT 116_184R |
|---|
| Synonyms |
H184-R |
|---|
| Accession |
CVCL_C3GH |
|---|
| Resource Identification Initiative |
To cite this cell line use: HCT 116_184R (RRID:CVCL_C3GH) |
|---|
| Comments |
Population: Caucasian.
Selected for resistance to: ChEBI; CHEBI_91353; 2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide (CI-1040; PD184352).
Derived from site: In situ; Colon; UBERON=UBERON_0001155. |
|---|
| Sequence variations |
- Mutation; HGNC; HGNC:173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line).
- Mutation; HGNC; HGNC:1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:9277; PPM1D; Simple; p.Leu450Ter (c.1349delT) (p.Leu450fs) (c.1344delT); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line).
|
|---|
| Disease |
Colon carcinoma (NCIt: C4910) |
|---|
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
|---|
| Hierarchy |
Parent: CVCL_0291 (HCT 116) |
|---|
| Sex of cell |
Male |
|---|
| Age at sampling |
48Y |
|---|
| Category |
Cancer cell line |
|---|
| Publications | PubMed=21447798; DOI=10.1126/scisignal.2001752
Annette S. Little, Kathryn Balmanno, Matthew J. Sale, Scott Newman, Jonathan R. Dry, Mark Hampson, Paul A.W. Edwards, Paul D. Smith, Simon J. Cook;
Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells.
Sci. Signal. 4:Ra17.1-Ra17.15(2011) |
|---|
| Cross-references |
|---|
| Cell line databases/resources |
cancercelllines; CVCL_C3GH
|
|---|
| Encyclopedic resources |
Wikidata; Q114311570
|
|---|
| Entry history |
|---|
| Entry creation | 22-Sep-2022 |
|---|
| Last entry update | 19-Dec-2024 |
|---|
| Version number | 6 |
|---|
